A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors
The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.
Breast Cancer
DRUG: Curcumin
Change in tumor proliferation rate, Change in tumor proliferation rate will be based on apoptosis (DNA fragmentation) and cell proliferation (Ki67) assays in biopsies pre and post treatment with curcumin, Up to 56 days
Number of adverse events reported, Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0, up to 84 days
The purpose of this study is to determine whether oral administration of Curcuma longa extract causes biological changes related to apoptosis (DNA fragmentation) and cell proliferation (Ki67) in primary tumors of breast cancer patients.